** Hong Kong shares of BeiGene Ltd 6160.HK jump 8.2% to HK$174.8, their highest since December 2021, and on course for fourth consecutive session of gains
** Stock on track for the biggest one-day rise since February 21
** Shanghai-listed stock 688235.SS surges 9.7% to record high at 248 yuan
** U.S. stock ONC.O jumped 7.5% on Thursday
** Chinese oncology treatments developer said its total global revenues increased 78% y/y to $1.1 bln for Q4 and it was up 55% y/y to $3.8 bln for the full year of 2024
** Full year 2025 revenue guidance of $4.9 bln to $5.3 bln - Co
** Nomura, with "Buy" rating on the stock, says 4Q24 sales beat on balanced growth in the U.S., China, EU with higher FY25E sales guided
** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both fall 1.8%, Hang Seng Index .HSI eases 1.7%
** Hong Kong-listed stock up 53.4% YTD, Shanghai shares up 50.6%, US shares up 50.7%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。